Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM01-STEM in sarcopenic obesity
NCT06600581Phase 2Active, not recruiting
- Sponsor
- Immunis, Inc.
- Start
- Dec 2024
- Primary completion
- Jul 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of IMM01-STEM in Sarcopenia, sponsored by Immunis, Inc.. Started Dec 2024; status: active, not recruiting.
02
Drugs
IMM01-STEM
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on NCT06600581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06600581.